linjc16/ctgov huggingface dataset:
Crystalloids for AKI in Shock Patients

Study Overview
=================
Brief Summary
-----------------
Fluid resuscitation is important in shock therapy, but the choice of fluids, especially the choice of crystalloid is under debate. It is said that normal saline is related to hyperchloremia， which might lead to acute kidney injury. Thus the hypothesis of the study is to explicit whether balanced salt solution could reduce the incidence of acute kidney injury when compared with normal saline.

Official Title
-----------------
Different Crystalloids on the Incidence of Acute Kidney Injury in Shock Patients

Conditions
-----------------
Shock

Intervention / Treatment
-----------------
* Drug: Fluid resuscitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Shock patients Exclusion Criteria: History of chronic renal failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Normal saline group<br>Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016. | Drug: Fluid resuscitation<br>* The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.<br>|
| Experimental: Balanced solution group<br>Shock patients who resuscitated with balanced solution were enrolled after June, 2016. | Drug: Fluid resuscitation<br>* The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of acute kidney injury | Diagnosis of acute kidney injury | 28-day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usage of renal replacement of therapy | Usage of CRRT | 28-day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
shock, crystalloid, acute kidney injury
Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if intravenous micronutrient therapy (IVMT) is effective in the treatment of fibromyalgia, as assessed by validated functional and pain measures.

Detailed Description
-----------------
As per Brief Summary

Official Title
-----------------
Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Drug: Intravenous micronutrient therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Meet the American College of Rheumatology criteria for Fibromyalgia diagnosis; On no medication for Fibromyalgia other than acetaminophen, or willing to stop all such medication for the duration of the study Willing to stop all FMS medication for the duration of the study or be on a stable dose of such medication for at least 3 months Exclusion criteria: Other concurrent medical conditions such as rheumatologic disease, chronic infection, untreated endocrine disorders, unstable seizures, psychiatric disorders, acute peptic ulcer disease, congestive heart failure, chronic liver disorders and/or bleeding problems Allergy to thiamin Unwilling to stop vitamin supplementation for the duration of the study PLEASE NOTE: Travel to and accomodations at the study site can NOT be compensated. Anyone wishing to travel from outside of the study site's geographic area must do so at their own risk and expense.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Intravenous micronutrient therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fibromyalgia, Intravenous micronutrient therapy, IVMT, alternative medicine, complementary medicine, vitamins, vitamin supplements
Surgical Decision Making Among People With Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
This is a study for people with inflammatory bowel disease (IBD--that is, ulcerative colitis, Crohn's colitis, or indeterminate colitis). We are studying how people with IBD decide to have surgery when a doctor has told them they should think about having their colon (large bowel) removed. This surgery is called a colectomy. Patients will be asked to fill out a questionnaire that takes about 60 to 90 minutes to complete. Questions ask about patients' background (age, etc.) and their IBD. They also ask about patients' decision to have surgery or not to have surgery. For instance, what kinds of things did they think about? Some questions ask about other people who affected the choice and how patients felt about the help they got from others. People who wish to join the study will receive payment to thank them for their time. Patients must be at least 18 years old Patients must speak English Patients must have been told by their doctor to think about having surgery to take out their colon to (a) lower their risk for cancer or (b) because they have pre-cancer (called dysplasia) Patients do not need to have had the surgery--they may have already had the surgery, they may not have had it yet, or they may have decided they do not want to have it

Official Title
-----------------
Surgical Decision Making Among People With Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have been told by a doctor that they have ulcerative colitis, Crohn's disease, or indeterminate colitis. Be at least 18 years old Speak English Have been told by a doctor to think about having surgery to take out their colon (colectomy) within the last 3 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine Disease stabilization/response rate after six 21-day cycles of ibrutinib Remission status after six, twelve and 20 21-day cycles of ibrutinib

Official Title
-----------------
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Conditions
-----------------
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Intervention / Treatment
-----------------
* Drug: Ibrutinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (key criteria): Histologically proven relapsed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) as confirmed by expert review Age at entry 18-99 years ECOG status 0-2 Absolute leukocyte count > 2.500/mm3 Absolute neutrophil count > 1.000/mm3 independent of growth factor support Platelet count > 100.000/mm3 or > 50.000/mm3 in case of bone marrow involvement independent of transfusion support in either situation GPT and GOT ≤ 3 x upper limit of normal (ULN) Exclusion Criteria (key criteria): Classical HL (cHL) or composite lymphoma Known central nervous lymphoma Prior Btk inhibitor treatment Life expectancy < 3 months Major surgery within 4 weeks of study inclusion History of stroke or intracranial hemorrhage within 6 months prior to the first study drug Current anticoagulation with warfarin or equivalent vitamin K antagonists

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ibrutinib<br>All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles | Drug: Ibrutinib<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response Rate |  | after 6 cycles (each cycle is 21 days) of Ibrutinib | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Remission status |  | Remission status after six, twelve and 20 21-day cycles of ibrutinib |
Prevena Incision Management System Wound Care

Study Overview
=================
Brief Summary
-----------------
Comparison of ventral hernia repair using standard wound care versus Prevena.

Detailed Description
-----------------
Compare the outcomes for patients who have abdominal reconstruction for ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™ to those patients who have ventral hernia repair to those who have standard wound care.

Official Title
-----------------
Use of Prevena Incision Management System in Wound Morbidity in Complex Ventral Hernia Patients. A Prospective Randomized Control Trial

Conditions
-----------------
Ventral Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 89 Open ventral hernia repair with or abdominal wall reconstruction after midline or non-midline defects. Able to provide informed consent Exclusion Criteria: Immunosuppresses patients Children 0 - 17

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arm 1<br>Ventral hernia repair using standard wound care. | |
| Arm 2<br>Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™ | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Objective for Wound Care Comparison | To quantify differences in the routine care of wound morbidity versus the use of Prevena™ by observing the healing process and obtaining quality of life by using the Carolinas Comfort Scale. | December 31, 2017 |
THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS

Study Overview
=================
Brief Summary
-----------------
Since both pathologies (PCOS and NAFLD) involve disturbed carbohydrate economy, which revolve around insulin resistance, it is tempting to examine the specific liver profile of women with PCOD. Furthermore, it would be of great importance if lean women who suffer from PCOD would be revealed to shere cardiovascular risks with their more overweight peers. Patients - women who will be diagnosed with PCOD following their initial referal to our fertility clinic. Controls - normal ovulatory women who approached our fertility clinic due to either unexplained or male factor infertility. Workup - history for menstrual pattern; Clinical evaluation for features of hyperandrogenism; ultrasonographic documentation of ovarian morphology; follicular phase hormonal profile for validation of the diagnosis and for ruling out other pathologies which may cause anovulation. Liver profiling - The following blood tests will be used for the biochemical profiling: fasting glucose and insulin, CRP, HDL-cholesterol, triglycerides, AST, ALT, GGT, LDH, alkaline phosphatase, total bilirubin, direct bilirubin, ferritin, HBA1C and micro albumin ratio. FibroScan® will be used to measure liver stiffness.

Conditions
-----------------
Polycystic Ovarian Syndrome,, Nonalcoholic Fatty Liver Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Workup - history for menstrual pattern; Clinical evaluation for features of hyperandrogenism; ultrasonographic documentation of ovarian morphology; follicular phase hormonal profile for validation of the diagnosis and for ruling out other pathologies which may cause anovulation. Liver profiling - The following blood tests will be used for the biochemical profiling: fasting glucose and insulin, CRP, HDL-cholesterol, triglycerides, AST, ALT, GGT, LDH, alkaline phosphatase, total bilirubin, direct bilirubin, ferritin, HBA1C and micro albumin ratio. FibroScan® will be used to measure liver stiffness, as previously described

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

Study Overview
=================
Brief Summary
-----------------
This is a bi-centric, prospective, open study comparing the effects of linagliptin on active GLP-1 concentrations in subjects with renal impairment compared to subjects with normal renal function.

Official Title
-----------------
EFFECTS OF LINAGLIPTIN ON ACTIVE GLP-1 CONCENTRATIONS IN SUBJECTS WITH RENAL IMPAIRMENT

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Linagliptin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have Type 2 diabetes mellitus based on the disease diagnostic criteria (WHO) classification Exclusion Criteria: Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Linagliptin in TD2 subjects<br>Linagliptin in TD2 subjects with normal renal function | Drug: Linagliptin<br> <br> |
| Experimental: Linagliptin in TD2 subjects with impaired renal function<br>Linagliptin in TD2 subjects with impaired renal function | Drug: Linagliptin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ΔAUCGLP-1-OGTT(0-240) | ΔAUCGLP-1-OGTT(0-240) Change in active GLP-1 concentrations after oral glucose ingestion after linagliptin Treatment compared between Groups. | Glucose tolerance test following 7 days of therapy |
An Intervention Program to Control Diabetes

Study Overview
=================
Brief Summary
-----------------
Study to evaluate the effectiveness of a structured intervention to improve diabetes control.

Official Title
-----------------
An Intervention Program to Control Diabetes

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Other: daily enteral nutritional product and/or behavioral changes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: informed consent 18-70 adults Type 2 Diabetes Males and non-pregnant females Exclusion Criteria: Use of exogenous insulin for glucose control Use of medications or supplements for weight loss Advanced diabetes complications Recent history of cardiovascular event

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: daily enteral nutritional product and/or behavioral changes|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c, Fasting blood glucose,blood pressure, weight loss |  | 24 weeks |
Impact of Neuropsychological Evaluation on Epilepsy Treatment

Study Overview
=================
Brief Summary
-----------------
The present study aims to expand the evidence base of neuropsychological services in the context of medical management of epilepsy, examining whether treatment outcome and patient satisfaction with medical care are significantly improved when neuropsychological evaluation is included as an additional component of medical care within a comprehensive epilepsy center. All participants will complete an initial survey and a follow-up survey regarding views towards their epilepsy treatment. Participants will be randomized into one of two groups. One group will be given a neuropsychological battery in addition to the survey. The primary study hypothesis is that the addition of neuropsychological services to treatment-as-usual will result in significant improvements in (a) satisfaction with medical care, (b) patient perceived treatment outcome, and (c) physician-rated medical compliance. The secondary hypothesis is that participants who undergo neuropsychological evaluation will be generally satisfied with their experience with neuropsychological services.

Official Title
-----------------
Impact of Neuropsychological Evaluation on Epilepsy Treatment

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Behavioral: Neuropsychological testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older experiencing some degree of epilepsy-related symptoms, but not of such severity as to preclude them from being able to provide consent or undergo neuropsychological assessment (requiring extended inpatient treatment, severely aphasic, or MMSE score < 25) Exclusion Criteria: Previously undergone neuropsychological testing Currently pursuing surgical treatment for epilepsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neuropsychological testing<br>Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys | Behavioral: Neuropsychological testing<br>* Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.<br>|
| No Intervention: Treatment as usual<br>Participants from this group will be administered the initial and follow-up survey. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epilepsy Outcome Study Survey | A brief questionnaire regarding the participants views on their epilepsy treatment | 2-4 months |
Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults

Study Overview
=================
Brief Summary
-----------------
This study tested the effects of resistant starch type 4 on blood sugar and hunger in young adults with Type 2 diabetes.

Detailed Description
-----------------
To measure the blood glucose response, after an overnight fast, blood samples were collected before eating and at 15, 30, 45, 60, 90, and 120 minutes after each each bar. The incremental area under the curve was used to calculate the glycemic index and insulin sensitivity via minimal model.

Official Title
-----------------
Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults

Conditions
-----------------
Hyperglycemia

Intervention / Treatment
-----------------
* Dietary Supplement: Resistant starch type 4 - raw
* Dietary Supplement: Resistant Starch Type 4 - Cooked
* Dietary Supplement: Dextrose
* Dietary Supplement: Puffed Wheat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Apparently Healthy (not diagnosed with disease) Young Adults (18-35) Exclusion Criteria: Diagnosed with diabetes or other metabolic disorders Allergies to Wheat Non-smokers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Resistant Starch Type 4-Raw | Dietary Supplement: Resistant starch type 4 - raw<br>* Dose: 80g bar containing Resistant Starch Type 4 - raw<br>|
| Experimental: 2<br>Resistant Starch Type 4-cooked | Dietary Supplement: Resistant Starch Type 4 - Cooked<br>* Dose: 80g bar containing Resistant Starch Type 4 - cooked<br>|
| Active Comparator: 3<br>Puffed wheat | Dietary Supplement: Puffed Wheat<br>* Dose: 80g bar containing puffed wheat cereal<br>|
| Placebo Comparator: 4<br>Dextrose | Dietary Supplement: Dextrose<br>* Dose: 7 oz of oral glucose tolerance beverage<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-Prandial Metabolism |  | Early morning | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Diet, Fiber, Age